DU
NKTR icon

Delphia (USA)’s Nektar Therapeutics NKTR Stock Holding History

Delphia (USA)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,133
Closed -$65K – 377
2022
Q2 		$65K Buy
+1,133
New +$71.5K 0.04% 367
2022
Q1 		– Sell
-1,258
Closed -$255K – 370
2021
Q4 		$255K Buy
+1,258
New +$273K 0.27% 150

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Delphia (USA)'s NKTR Position: Q3 2022 in Review

Delphia (USA) sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 1,133 shares — an estimated $65K sold.

Delphia (USA) first reported a position in NKTR in Q4 2021 and held it in 2 quarters. The position peaked at $255K in Q4 2021. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Delphia (USA) reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Delphia (USA) sold 1,133 Nektar Therapeutics shares in Q3 2022, an estimated $65K.
  • Delphia (USA) first reported a position in Nektar Therapeutics in Q4 2021 and held it in 2 quarters.
  • Delphia (USA)'s Nektar Therapeutics position peaked at $255K in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.